Glaukos
GKOS
Market cap $5.93B

103.81 USD

-2.74

2.57%

At close Jul 11, 4:00 PM EDT

After hours

103.81

+0.00

0.00%

1 day

-2.57%

5 days

0.05%

1 month

4.70%

3 months

15.25%

6 months

-31.65%

Year to date

-30.65%

1 year

-15.77%

5 years

166.18%

10 years

246.03%

About: Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Employees: 995

Healthcare Medical Devices

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 113

5% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 57

2% less funds holding

Funds holding: 321 [Q4 2024] → 314 (-7) [Q1 2025]

2.99% less ownership

Funds ownership: 103.62% [Q4 2024] → 100.63% (-2.99%) [Q1 2025]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 4 (-2) [Q1 2025]

34% less capital invested

Capital invested by funds: $8.57B [Q4 2024] → $5.65B (-$2.92B) [Q1 2025]

64% less call options, than puts

Call options by funds: $27.9M | Put options by funds: $77.9M

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$72

31%

downside

Avg. target

$122

18%

upside

High target

$175

69%

upside

8 analyst ratings

6 positive

75%

1 neutral

13%

1 negative

13%

Morgan Stanley Patrick Wood	31%downside $72	Underweight Maintained	6 May 2025
Stephens & Co. Mason Carrico	11%upside $115	Overweight Maintained	2 May 2025
Stifel Thomas Stephan	11%upside $115	Buy Maintained	1 May 2025
Truist Securities Richard Newitter	30%upside $135	Buy Reiterated	1 May 2025
Wells Fargo Larry Biegelsen	17%downside $86	Equal-Weight Downgraded	1 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about GKOS published over the past 30 days

Zacks Investment Research

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025. A link to the.

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular.

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025. "Ringing the NYSE closing bell today is a proud and hu.

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Zacks Investment Research

What Makes Glaukos (GKOS) a New Buy Stock

Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Glaukos (GKOS) a New Buy Stock

Zacks Investment Research

Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Here's Why You Should Retain Glaukos Stock in Your Portfolio

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 12:30 p.m. ET William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025.

Glaukos Announces Participation in Upcoming Investor Conferences

Zacks Investment Research

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline

Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline

See News Rankings

Charts implemented using Lightweight Charts™